What are the recommended treatments for macular amyloidosis?

Treatment of Macular Amyloidosis

For macular amyloidosis, fractional CO2 laser is the most effective treatment option, with evidence showing complete clearance of lesions and significant reduction in amyloid deposition. 1

Primary Treatment Approach

First-Line: Fractional CO2 Laser

• CO2 laser achieved complete clearance in all treated areas in comparative studies, making it superior to other laser modalities 1
• Treatment protocol: 4 monthly sessions using energies of 4 and 3.5 microjoules for first and second passes
• Both fractional CO2 laser alone and combined with DMSO 50% show significant efficacy:
  • Significant decrease in pigmentation (p < 0.001)
  • Median itching score drops from 9 to 3.5 (laser alone) or 2 (laser + DMSO)
  • Histopathologically confirmed reduction in amyloid deposition 2

The addition of DMSO 50% after laser treatment does not provide statistically significant additional benefit, though it may offer marginal improvement in pruritus 2

Alternative Laser Options (When CO2 Unavailable)

Q-switched Nd:YAG laser (1064 nm) and Er:YAG laser (2940 nm) are reasonable alternatives:

• Both improve pruritus significantly (p < 0.001)
• No significant difference between these two modalities in outcomes
• Protocol: 4 sessions at 4-week intervals
• Q-switched Nd:YAG parameters: 5 J/cm², 4mm spot size, 10 Hz frequency 3

Important caveat: Q-switched Nd:YAG was effective in only 3 of 17 patients when compared head-to-head with CO2 laser, making it clearly inferior 1

Pulsed dye laser (PDL) should be avoided - no desirable results obtained in comparative trials 1

Adjunctive Treatments

Microneedling-Based Approaches

• Microneedling alone provides meaningful improvement:
  • Reduces pigmentation and rippling pattern
  • Improves pruritus by 61.66% after 4 sessions
  • Patient satisfaction ~47%
  • Treatment interval: every 2 weeks for 4 sessions 4

Adding topical tranexamic acid to microneedling provides no additional benefit (p > 0.05) 4

Intralesional Tranexamic Acid

When laser therapy is not feasible, intralesional tranexamic acid is more effective than topical Kligman combination:

• ΔE reduced from 11.39 to 8.53 over 3 sessions (vs. 8.79 to 6.32 with Kligman)
• Lower pruritus scores compared to Kligman
• Significantly greater improvements in hyperpigmentation (p < 0.05)
• Trade-off: tolerable injection pain but less local pruritic discomfort 5

Treatment Algorithm

1. First choice: Fractional CO2 laser (4 monthly sessions)

   • Consider adding DMSO 50% if pruritus is particularly severe, though benefit is marginal

2. If CO2 laser unavailable: Q-switched Nd:YAG 1064nm or Er:YAG 2940nm

   • Expect lower efficacy than CO2

3. If lasers contraindicated or unavailable: Intralesional tranexamic acid

   • Superior to topical depigmenting agents

4. For mild cases or adjunctive therapy: Microneedling alone

   • Do not add topical tranexamic acid (no added benefit)

5. Avoid: Pulsed dye laser (ineffective), topical tranexamic acid with microneedling (no benefit over microneedling alone)

Common Pitfalls

• Do not confuse macular amyloidosis with systemic AL amyloidosis - the evidence provided about AL amyloidosis (daratumumab, bortezomib, ASCT) [@1-6@] is completely irrelevant to cutaneous macular amyloidosis, which is a localized dermatologic condition requiring physical removal of deposited protein
• Do not rely on topical corticosteroids as definitive therapy - while they may provide symptomatic relief, they do not address amyloid deposition 6
• Do not expect topical agents to significantly alter disease course - physical removal via laser is superior to chemical approaches